Loading stock data…
RNA
$13.43+0.66 (+5.17%)
Market ClosedLast close May 1
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.43
Potential Upside
5%
Whystock Fair Value$14.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include A...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$214.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.99%
Volume
Today's trading volume
168,987
Recent News
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is an oral treatment being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors.
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
Novartis (SWX:NOVN) issues US$11b in US dollar bonds to fund its planned US$12b acquisition of Avidity Biosciences. The bond financing highlights the company’s focus on expanding its medicines portfolio through large-scale M&A. Separately, Novartis signs a licensing agreement with Unnatural Products for macrocyclic peptide therapeutics targeting cardiovascular disease. Both moves add new platforms and modalities to the Novartis pipeline beyond recent product approvals and corporate...
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Seven-tranche bond sale helps repay bridge loan tied to Avidity acquisition, amid $26 billion investment-grade issuance surge.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State